WHWei-Han Hu

Wei-Han Hu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Wei-Han Hu has a total of 72 co-authors. Here are the top co-authors by number of shared publications:

  • Rui Sun

    Department of Radiation Oncology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, People's Republic of China

    3 shared publications
  • Xiuyu Cai

    State Key Laboratory of Oncology in South China, Cancer Center, Sun Yat-Sen University, Guangzhou, China

    3 shared publications
  • Bojin Su

    Department of Pathophysiology, Zhongshan School of Medicine, Sun Yat-Sen University, Guangzhou 510080, Guangdong Province, PR China

    2 shared publications
  • Donghui Wang

    Department of Pathophysiology, Zhongshan School of Medicine, Sun Yat-Sen University, Guangzhou 510080, Guangdong Province, PR China

    2 shared publications
  • Gui-Fang Guo

    State Key Laboratory of Oncology in South China, Cancer Center, Sun Yat-Sen University, Guangzhou

    2 shared publications
  • Guoyi Zhang

    Department of Radiation Oncology, Cancer Center, First People's Hospital of Foshan, Foshan 528000, Guangdong Province, PR China

    2 shared publications

Latest Publications

  • Open Access

    Meta-analysis of the clinical characteristics and prognostic relevance of NOTCH1 and FBXW7 mutation in T-cell acute lymphoblastic leukemia

    by Rong-Bin Liu, Jian-Gui Guo, Tian-Ze Liu, Cheng-Cheng Guo, Xin-Xiang Fan, Xiao Zhang, Wei-Han Hu, Xiu-Yu Cai

    // <![CDATA[ $('.header-date').hide();$('#titleAuthors').hide();$('#abstractHeader').hide(); // ]]> Rong-Bin Liu1, 2, 3, *, Jian-Gui Guo1, 2, 4, 8, *, Tian-Ze Liu1, 2, *, Cheng-Cheng Guo1, 2, 5, Xin-Xiang Fan6, Xiao Zhang1, 2, 3, Wei-Han Hu1, 2, 4 and Xiu-Yu Cai1, 2, 7 1State Key Laboratory of Oncology in South China, Guangzhou, China 2Collaborative Innovation Center for Cancer Medicine, Guangzhou, China 3Department of Molecular Diagnostics, Sun Yat-Sen University Cancer Center, Guangzhou, China 4Department of Radiation Oncology, Sun Yat-Sen University Cancer Center, Guangzhou, China 5Department of Neurosurgery, Sun Yat-Sen University Cancer Center, Guangzhou, China 6Department of Urology, Sun Yat-Sen Memorial Hospital, Guangzhou, China 7Department of VIP Region, Sun Yat-Sen University Cancer Center, Guangzhou, China 8Department of Radiation Oncology, The First People's Hospital of Foshan, Foshan, China *These authors contributed equally to this work Correspondence to: Xiu-Yu Cai, email: caixy@sysucc.org.cn Wei-Han Hu, email: huwh@sysucc.org.cn Keywords: T-ALL, NOTCH1, FBXW7, prognosis, meta-analysis Received: September 20, 2016 Accepted: April 26, 2017 Published: June 19, 2017 ABSTRACT The NOTCH1 signaling pathway is crucial for T-cell development, and NOTCH1 and/or FBXW7 mutations are frequently detected in T-cell acute lymphoblastic leukemia (T-ALL). We performed a systematic review and meta-analysis of 18 randomized controlled trials (RCTs) to assess the prognostic impact of mutations in the NOTCH1 pathway. After retrieving relevant articles from PubMed, EMBASE, and the Cochrane Library, we investigated overall survival (OS) and event-free survival (EFS) with hazard ratios (HRs) using fixed-effects or random-effects models and conducted subgroup analyses based on population and mutation status. NOTCH1/FBXW7 mutations correlated significantly with better prognosis (5-year EFS: HR, 0.57; 95% confidence interval [CI], 0.46 to 0.68; P < 0.001 and 5-year OS: HR, 0.61; 95% CI, 0.51 to 0.74; P < 0.001). The HR for 5-year EFS and OS with NOTCH1 mutations were 0.63 (95% CI, 0.53 to 0.75) and 0.76 (95% CI, 0.60 to 0.95), respectively; with FBXW7 mutations, they were 0.82 (95% CI, 0.60 to 1.11) and 0.79 (95% CI, 0.55 to 1.12), respectively. However, differences between children and adults showed no significance. We conclude that the presence of NOTCH1/FBXW7 mutations is an independent prognostic factor for 5-year EFS and 5-year OS.


  • Open Access

    DNA-dependent protein kinase catalytic subunit functions in metastasis and influences survival in advanced-stage laryngeal squamous cell carcinoma

    by Sha-Sha He, Yong Chen, Xiao-Ming Shen, Hong-Zhi Wang, Peng Sun, Jun Dong, Gui-Fang Guo, Ju-Gao Chen, Liang-Ping Xia, Pei-Li Hu, et al.

    Background: DNA-dependent protein kinase catalytic subunit (DNA-PKcs) is known to function in several types of cancer. In this study, we investigated the expression and clinicopathologic significance of DNA-PKcs in laryngeal squamous cell carcinoma (LSCC). Methods: We conducted a retrospective study of 208 patients with advanced-stage LSCC treated at Sun Yat-sen University Cancer Center, Guangzhou, China. We assessed DNA-PKcs and p16INK4a (p16) status using immunohistochemistry. We examined the association between DNA-PKcs expression and clinicopathologic features and survival outcomes. To evaluate the independent prognostic relevance of DNA-PKcs, we used univariate and multivariate Cox regression models. We estimated overall survival (OS) and distant metastasis-free survival (DMFS) using the Kaplan-Meier method. Results: Immunohistochemical analyses revealed that 163/208 (78.4%) of the LSCC tissue samples exhibited high DNA-PKcs expression. High DNA-PKcs expression was significantly associated with survival outcomes (P = 0.016) and distant metastasis (P = 0.02; chi-squared test). High DNA-PKcs expression was associated with a significantly shorter OS and DMFS than low DNA-PKcs expression (P = 0.029 and 0.033, respectively; log-rank test), and was associated with poor OS in the p16-positive subgroup (P = 0.047). Multivariate analysis identified DNA-PKcs as an independent prognostic indicator of OS and DMFS in all patients (P = 0.039 and 0.037, respectively). Conclusions: Our results suggest that patients with LSCC in whom DNA-PKcs expression is elevated have a higher incidence of distant metastasis and a poorer prognosis. DNA-PKcs may represent a marker of tumor progression in patients with p16-positive LSCC.


  • Open Access

    Loss of LKB1 Expression Decreases the Survival and Promotes Laryngeal Cancer Metastasis

    by Sha-Sha He, Yong Chen, Hong-Zhi Wang, Xiao-Ming Shen, Peng Sun, Jun Dong, Xin-Biao Liao, Gui-Fang Guo, Ju-Gao Chen, Liang-Ping Xia, et al.

    Background: Given recent results indicating that diminished LKB1 expression in laryngeal cancer correlates with shorter survival. We aim to perform an analysis estimate the role of decreased liver kinase B1(LKB1) and in the prognostication of human laryngeal squamous cell carcinoma (LSCC).


  • Open Access

    ABO blood group is a predictor of survival in patients with laryngeal cancer

    by Ting Jin, Pei-Jing Li, Xiao-Zhong Chen, Wei-Han Hu

    Whether the ABO blood group is associated with the survival of patients with laryngeal cancer remains unknown. The purpose of this study was to investigate the association between the ABO blood group and clinicopathologic characteristics of patients with laryngeal cancer and assess whether the ABO blood group was associated with prognosis. We analyzed the records of 1260 patients with laryngeal cancer who underwent curative treatment at Sun Yat-sen University Cancer Center between January 1993 and December 2009. The Chi-square test was used to assess the relationship between the ABO blood group and clinicopathologic characteristics. The Kaplan–Meier method was used to estimate 3-, 5-, and 10-year overall survival (OS) rates. The Cox proportional hazards model was used in univariate and multivariate analyses of OS. No significant association was found between the ABO blood group and clinicopathologic characteristics except for primary tumor site. The median OS for patients with blood groups A, B, AB, and O were 87.0, 80.0, 90.0, and 72.5 months, respectively. The 3-, 5-, and 10-year OS rates were 82.4%, 76.0%, and 67.5% for patients with blood group A; 77.4%, 69.8%, and 58.4% for patients with blood group B; 82.2%, 73.1%, and 65.6% for patients with blood group AB; and 71.7%, 66.4%, and 55.5% for patients with blood group O, respectively. Univariate and multivariate analyses showed that the ABO blood group had significant effects on prognosis in patients with laryngeal cancer. The ABO blood group is associated with survival in patients with laryngeal cancer. Patients with blood group O had significantly shorter OS than patients with other ABO blood groups.


  • Open Access

    Effect of Prolonged Radiotherapy Treatment Time on Survival Outcomes after Intensity-Modulated Radiation Therapy in Nasopharyngeal Carcinoma

    by Pei-Jing Li, Ting Jin, Dong-Hua Luo, Ting Shen, Dong-Mei Mai, Wei-Han Hu, Hao-Yuan Mo

    To estimate the influence of prolonged radiation treatment time (RTT) on survival outcomes in nasopharyngeal carcinoma after continuous intensity-modulated radiation therapy. Retrospectively review 321 patients with NPC treated between October 2009 and December 2010 and all of them underwent simultaneous accelerated intensity-modulated radiation therapy. The fractionated dose was 2–2.47 Gy/F (median 2.27 Gy), and the total dose for nasopharyngeal region was 64–74 Gy/ 28–33 fractions. The association of prolonged RTT and treatment interruption with PFS, LRFS and DFFS were assessed by univariate analysis and multivariate analysis. Survival analyses were carried out using Kaplan–Meier methodology and the log-rank test was used to assess the difference. The Cox regression proportional hazard model was used for multivariate analyses and evaluating the prognostic parameters for PFS, LRFS and DFFS. Univariate analysis revealed no significant associations between prolonged RTT and PFS, LRFS, DFFS when dichotomized using various cut-off values (all P>0.05). In multivariate analysis, RTT (range, 36–63 days) as a continuous variable, had no influence on any survival outcome as well (P>0.05). T and N classification were independent prognostic factors for PFS, LRFS and DFFS (all PP = 0.057). Age was an independent prognostic factor for PFS (hazard ratio [HR], 1.033; P = 0.008) and DFFS (HR, 1.032; P = 0.043). We conclude that no such association between survival outcomes and radiation treatment duration (range: 36–63 days) can be found in the present retrospective study, however, we have to remind that prolongation in treatment should be limited in clinical application and interruptions caused by any reason should be minimized as much as possible.


  • HPV Infection and Anemia Status Stratify the Survival of Early T2 Laryngeal Squamous Cell Carcinoma

    by Hongzhi Wang, Zichen Zhang, Rui Sun, Hui Lin, Long Gong, Minjie Fang, Wei-Han Hu


  • Clinical implications of hepatitis B viral infection in Epstein–Barr virus-associated nasopharyngeal carcinoma

    by Tao Xu, Zeli Huang, Yanming Deng, Sumei Wang, Bojin Su, Weihong Wei, Donghui Wang, Jun Jiang, Anfei Li, Guoyi Zhang, et al.


  • Prognostic significance of circulating CD19+ B lymphocytes in EBV-associated nasopharyngeal carcinoma

    by Tao Xu, Zheli Huang, Bojin Su, Sumei Wang, Donghui Wang, Chunhua Wang, Weihong Wei, Jun Jiang, Guoyi Zhang, Huiling Yang, et al.

    In this retrospective study, the correlation between pre- and post-treatment plasma Epstein–Barr virus (EBV) DNA and circulating immune subsets as well as the prognostic implications was investigated in nasopharyngeal carcinoma (NPC) patients. Patients (n = 356) were diagnosed and received comprehensive treatment at the First People’s Hospital of Foshan from 2006 to 2010. Pre- and post-treatment plasma EBV DNA load and circulating immune subsets (percentage of CD3+ T cell, CD3+ CD4+ T cells, CD3+ CD8+ T cells, CD19+ B cells and CD56+ NK cells) were analyzed by real-time PCR and flow cytometry. Patient age correlated negatively with CD3+ T cells (r = −0.264, P = 0.001) and positively with CD56+ NK cells (r = 0.272, P = 0.001). Pre-treatment plasma EBV DNA correlated negatively with CD19+ B cells (r = −0.223, P = 0.009) and CD4/CD8 ratio (r = −0.177, P = 0.047). Patients with low CD19+ B cell had poorer 5-year progression-free survival (PFS) (66.6 vs. 81.8 %, P = 0.036) and 5-year overall survival (OS) (70.5 vs. 81.5 %, P = 0.097) than patients with high CD19+ B cells. Low CD19+ B cells was identified as a negative prognostic factor for 5-year PFS (hazard ratio [HR] 0.487; P = 0.040), but not for 5-year OS (HR 0.550; P = 0.102) in multivariate analysis. Post-treatment plasma EBV DNA was the most important prognostic factor for 5-year PFS (HR 2.983; P = 0.006) and 5-year OS (HR 3.927; P


  • Open Access

    P16INK4Aas a surrogate biomarker for human papillomavirus-associated oropharyngeal carcinoma: Consideration of some aspects

    by Hongzhi Wang, Rui Sun, Hui Lin, Wei-Han Hu

    Human papillomavirus (HPV)‐associated oropharyngeal squamous cell carcinomas (OPSCCs) frequently show different clinical and pathological features, which tend to be younger age, better performance status, less tobacco and alcohol consumption, more poorly differentiated histopathology, but usually with better treatment response and prognosis compared with HPV‐negative OPSCCs. In tumor tissue, HPV infection is closely correlated with p16INK4A expression, which has been suggested to be a surrogate biomarker of HPV infection. However, there is diversity of sensitivity and specificity about p16INK4A in surrogate detection of HPV status. Herein, we summarize the current knowledge and note some aspects for consideration concerning p16INK4A as a surrogate biomarker for HPV‐associated OPSCC.